Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the association between polycystic ovarian syndrome and hypertension, highlighting evidence of metabolic factors influencing this potential link and stressing the need for further research in this area.

Deep Brain Stimulation helps manage Parkinson's symptoms when medication isn't enough.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.

This study found that the revised BASP classification for pattern hair loss, which addresses certain limitations of the original, could serve as an alternative option despite a decrease in clinical accuracy and ease of use.

Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.

In an outpatient cardiology center, this study found that introducing the AHA/ACC ABI screening protocol significantly increased the frequency of ABI ordering by 31.6% for symptomatic patients.

This study suggests that BTP levels in cerebrospinal fluid might help diagnose CIDP and predict therapy response but require validation in larger cohorts.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

This study found that the serine protease BSSP is strongly expressed in mouse skin during carcinogenesis and is upregulated independently of c-Fos and unaffected by glucocorticoids.

This study found that a novel saw palmetto supercritical CO2 extract effectively inhibits 5α-reductase type II in vitro, suggesting its potential for promoting prostate health in benign prostatic hyperplasia.

In a cell-free test setting, this study found that a novel saw palmetto extract effectively inhibited the 5α-reductase type II enzyme, showing promising bioactivity comparable to finasteride for promoting prostate health.

In this study, the combination of Serenoa repens extract with Phenolmicin P3 and Bosexil suppositories significantly improved lower urinary tract symptoms and decreased PSA levels in patients with benign prostatic obstruction-related symptoms.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

This retrospective study observed no significant difference in the prevalence of incidental prostate cancer between suprapubic prostatectomy and transurethral prostate resection groups, with most tumors being well differentiated and early-stage.

This study explored the effects of a 50% hydroalcoholic UPBF extract on BPH in testosterone propionate-induced rats, finding significant improvements in prostate-related parameters and lower urinary tract symptoms at a 200 mg/kg dose, suggesting potential use in BPH management.

This source reports that Serenoa repens may be an effective and safe natural remedy for treating benign prostatic hyperplasia, possibly working through mechanisms like apoptosis stimulation, 5-alpha-reductase inhibition, and blocking DHT receptor interactions, with minimal side effects.

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

In this retrospective study, researchers found that coadministration of finasteride and sildenafil in patients with benign prostatic hyperplasia improved both lower urinary tract symptoms and sexual function, without significant changes in vital signs, after a treatment period averaging 18 weeks.

This study introduced the BASP classification, a new system for categorizing pattern hair loss in both men and women, and applied it to analyze 2213 Korean subjects.

This study demonstrated that the Epidermal Biopotential Sensing System (EBSS) can measure digital biomarkers of pain in mice, suggesting potential applications in assessing pain and screening analgesics in populations with communication difficulties.

PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.

The abstract discusses that Serenoa repens, a commonly used phytotherapeutic agent, may play a crucial role as an alternative or complementary treatment for lower urinary tract symptoms in patients with benign prostatic hyperplasia, particularly those with mild-to-moderate disease severity.

In this placebo-controlled study, finasteride significantly improved symptoms, reduced prostate size, and increased urine flow rate in patients with moderately symptomatic BPH over two years.

This study reported that specific inhibition of the classical complement pathway with BIVV009 prevented C3 deposition along the dermal-epidermal junction in bullous pemphigoid, reflecting its potential efficacy.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.